[Correspondence] Clinical benefits of selumetinib in adults with neurofibromatosis type 1

The KOMET study1 is a landmark achievement, being the first randomised, placebo-controlled trial to demonstrate the efficacy of selumetinib in adult patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. However, the interpretation of selumetinib's clinical benefits, particularly in the discussion of the objective response rate (ORR), invites a more cautious and comparative appraisal. Although the trial reports a statistically significant ORR of 20% in the selumetinib group versus 5% in the placebo group by cycle 16 (p=0·011), this result requires further contextualisation.